DNAprint Genomics (DNAG)

[worktoplay]

goliath...It means that the target identification and initial drug development work through Phase I were done by another company, and Biofrontera has purchased a license to take the drug from Phase II through to market. They basically own the rights to the drug now.

Likely there is a royalty agreement allowing the initial developer to share some of the profits when/if it reaches commericalization.

Hope this helps...

W2P